Cushing's syndrome Medical Services in China

Cushing's syndrome is a rare endocrine disorder characterized by chronic exposure to excessive levels of cortisol — a glucocorticoid hormone produced by the adrenal cortex. This hypercortisolism may arise from endogenous sources (e.g., pituitary adenoma causing Cushing’s disease, adrenal adenoma or carcinoma, or ectopic ACTH secretion) or exogenous causes (prolonged high-dose glucocorticoid therapy). Pathogenesis hinges on dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis: in Cushing’s disease (the most common endogenous form, accounting for ~70% of cases), a benign corticotroph adenoma secretes excess adrenocorticotropic hormone (ACTH), stimulating bilateral adrenal hyperplasia and cortisol overproduction. Adrenal tumors autonomously secrete cortisol independent of ACTH, while ectopic ACTH syndrome — often linked to small-cell lung cancer or neuroendocrine tumors — results in markedly elevated ACTH and cortisol with suppressed CRH and ACTH from the pituitary. Epidemiologically, Cushing’s syndrome affects approximately 1–2.5 per million people annually, with a female-to-male ratio of 3:1 and peak incidence between ages 20 and 50. Risk factors include long-term systemic corticosteroid use (e.g., for autoimmune diseases or transplant recipients), genetic predispositions (e.g., MEN1, PRKAR1A, or APC mutations in familial syndromes), obesity-related HPA axis dysregulation, and underlying neoplasms. Clinical manifestations are multisystemic: central obesity, moon facies, dorsocervical fat pad ('buffalo hump'), purple striae, thin skin with easy bruising, proximal muscle weakness, hypertension, glucose intolerance or overt diabetes mellitus, osteoporosis, menstrual irregularities, hirsutism, mood disturbances (depression, anxiety, cognitive fog), and increased susceptibility to infections. These features profoundly impair quality of life: patients report fatigue limiting daily function, body image distress due to visible stigmata, sexual dysfunction, social withdrawal, reduced work capacity, and heightened psychological burden — with studies showing significantly lower SF-36 physical and mental component scores compared to age-matched controls. Early diagnosis remains challenging due to symptom overlap with metabolic syndrome and depression; delayed recognition increases morbidity (e.g., cardiovascular events, vertebral fractures, opportunistic infections) and mortality. Multidisciplinary evaluation — including late-night salivary cortisol, 24-hour urinary free cortisol, low-dose dexamethasone suppression test, and dynamic imaging (pituitary MRI, adrenal CT/MRI, or PET-CT for ectopic sources) — is essential for accurate subtyping and treatment planning.

Cushing's syndrome is a heterogeneous endocrine disorder characterized by chronic exposure to excessive glucocorticoids, leading to multisystem morbidity including central obesity, glucose intolerance, hypertension, osteoporosis, proximal muscle weakness, skin fragility, and psychiatric disturbances. The etiology is broadly categorized as exogenous (iatrogenic) or endogenous, with distinct pathophysiological mechanisms and clinical implications.

Exogenous glucocorticoid administration is the most common cause worldwide, accounting for over 80% of cases. Prolonged therapeutic use—particularly at doses exceeding 7.5 mg/day of prednisone (or equivalent) for >3–6 weeks—suppresses the hypothalamic-pituitary-adrenal (HPA) axis and induces classic Cushingoid features. Common indications include autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis), asthma, inflammatory bowel disease, organ transplantation, and certain malignancies. Dose, duration, route (oral > inhaled > intra-articular), and pharmacokinetic properties (e.g., long half-life of dexamethasone) significantly influence risk.

Endogenous Cushing's syndrome arises from autonomous cortisol overproduction and is subdivided into ACTH-dependent and ACTH-independent forms. ACTH-dependent disease constitutes ~80% of endogenous cases and is most frequently due to pituitary corticotroph adenomas (Cushing’s disease), representing ~70% of all endogenous cases. Ectopic ACTH secretion—typically from neuroendocrine tumors (e.g., small-cell lung carcinoma, bronchial carcinoids, thymic carcinoids, pancreatic NETs)—accounts for ~10–15% and is often associated with rapid-onset, severe hypercortisolism, hypokalemia, and hyperpigmentation. Rarely, ectopic CRH secretion may mimic ACTH-dependent disease.

ACTH-independent Cushing’s syndrome results from primary adrenal pathology: unilateral adrenocortical adenomas (benign, cortisol-secreting), adrenocortical carcinomas (malignant, often aggressive with high cortisol and androgen output), and primary bilateral macronodular or micronodular adrenal hyperplasia (PBMAH, PEMA). PBMAH may be associated with aberrant G-protein coupled receptor expression (e.g., gastric inhibitory polypeptide [GIP], beta-adrenergic, serotonin receptors), leading to food- or posture-dependent cortisol secretion. Familial forms include McCune-Albright syndrome (GNAS mutations), Carney complex (PRKAR1A germline mutations), and isolated micronodular adrenal hyperplasia linked to ARMC5 mutations (autosomal dominant, with incomplete penetrance).

Genetic factors contribute significantly in specific subsets. Germline mutations in MEN1 (multiple endocrine neoplasia type 1), CDKN1B (MEN4), and AIP are associated with pituitary adenomas predisposing to Cushing’s disease. ARMC5 mutations underlie up to 25% of apparently sporadic PBMAH cases and confer increased risk of bilateral disease and recurrence. PRKAR1A loss-of-function mutations define Carney complex, which includes pigmented adrenal nodules and Cushing’s syndrome in ~25% of affected individuals. TP53 germline mutations (Li-Fraumeni syndrome) increase susceptibility to adrenocortical carcinoma.

Environmental and modifiable risk factors are limited but noteworthy. Chronic psychological stress does not cause Cushing’s syndrome, though it may exacerbate metabolic comorbidities. Obesity-related hypercortisolism ("pseudo-Cushing's") reflects HPA axis dysregulation without autonomous cortisol excess and must be differentiated via dynamic testing. Medications such as ritodrine (a beta-2 agonist used historically in preterm labor) and certain antidepressants (e.g., tricyclics) may transiently elevate cortisol but do not induce true Cushing’s syndrome. Smoking is associated with earlier onset and more aggressive behavior in adrenocortical carcinoma, possibly via oxidative stress and p53 pathway modulation. Environmental endocrine disruptors (e.g., bisphenol A, phthalates) remain investigational; while they may perturb steroidogenesis in vitro, no robust epidemiologic evidence links them to clinical Cushing’s syndrome.

Demographic risk factors include female sex (3–5:1 female-to-male ratio in Cushing’s disease), age (peak incidence 20–50 years for pituitary and adrenal adenomas; older age for ectopic ACTH), and race (higher prevalence of ectopic ACTH among Black individuals, potentially reflecting disparities in cancer screening and diagnosis). Prior history of adrenal incidentaloma, especially with hormonal autonomy or growth, increases surveillance urgency. Patients with unexplained weight gain, new-onset diabetes mellitus refractory to standard therapy, or progressive osteoporosis warrant systematic evaluation for hypercortisolism. Early recognition and subtype-specific management—transsphenoidal surgery for Cushing’s disease, resection for adrenal tumors, tumor-directed therapy for ectopic sources—are critical to mitigate long-term cardiovascular, infectious, and thromboembolic risks.

Cushing's syndrome is a heterogeneous endocrine disorder characterized by chronic exposure to excessive glucocorticoids—either endogenous (due to ACTH-dependent or ACTH-independent hypercortisolism) or exogenous (iatrogenic). It predominantly falls under the purview of endocrinology and requires meticulous clinical recognition, as delayed diagnosis significantly increases morbidity and mortality. Early symptoms are often subtle, nonspecific, and easily misattributed to stress, aging, or lifestyle factors, leading to diagnostic delays averaging 3–5 years. Patients commonly present with progressive fatigue, unexplained weight gain—particularly central adiposity—and new-onset or worsening hypertension. Psychological manifestations such as irritability, anxiety, emotional lability, and mild cognitive slowing (e.g., impaired concentration and memory retrieval) frequently precede overt physical signs. Menstrual irregularities (oligo- or amenorrhea) in premenopausal women and decreased libido or erectile dysfunction in men may be among the earliest endocrine clues. Easy bruising, persistent facial flushing, and recurrent skin infections (e.g., folliculitis or candidiasis) also emerge early but are frequently overlooked.

Typical symptoms reflect the systemic consequences of prolonged cortisol excess. Central obesity—with characteristic accumulation in the abdomen, supraclavicular fat pads ('buffalo hump'), and rounded, plethoric 'moon face'—is nearly universal in moderate-to-severe cases. Proximal muscle weakness, especially involving hip flexors and shoulder girdle muscles, impairs stair climbing and rising from seated positions; this reflects cortisol-induced myopathy and type II fiber atrophy. Skin changes include thin, translucent epidermis with prominent vasculature, violaceous striae (>1 cm wide, typically on abdomen, thighs, and breasts), poor wound healing, and acneiform eruptions. Hirsutism (in women) and temporal hair recession (in men) reflect cortisol’s modulation of androgen metabolism and SHBG suppression. Hypertension occurs in >80% of patients due to enhanced vascular sensitivity to catecholamines, mineralocorticoid receptor activation (via cortisol-induced 11β-HSD2 saturation), and renal sodium retention. Glucose intolerance or overt type 2 diabetes mellitus develops in ~50% of cases secondary to hepatic gluconeogenesis stimulation, peripheral insulin resistance, and β-cell dysfunction.

Accompanying symptoms further support the diagnosis and reflect multisystem involvement. Osteopenia or osteoporosis manifests clinically as vertebral compression fractures (often painless), height loss, or kyphosis; biochemical markers include elevated bone resorption (e.g., serum CTX, urinary NTX) and suppressed PTH-related peptide. Patients report polyuria and polydipsia secondary to cortisol-induced inhibition of ADH release and renal medullary washout, mimicking nephrogenic diabetes insipidus. Immunosuppression predisposes to recurrent upper respiratory infections, herpes zoster reactivation, and atypical presentations of tuberculosis or fungal infections. Psychiatric comorbidities include major depressive disorder (prevalence ~50%), insomnia, and, less commonly, psychosis or mania—especially in Cushing’s disease with rapid-onset hypercortisolism. Children exhibit growth deceleration and delayed puberty due to GH/IGF-1 axis suppression and gonadotropin inhibition.

Complications arise from sustained hypercortisolism and substantially impact prognosis. Cardiovascular complications include accelerated atherosclerosis, left ventricular hypertrophy, heart failure, and increased risk of myocardial infarction and stroke. Thromboembolic events—deep vein thrombosis and pulmonary embolism—are markedly elevated (4–6-fold higher than general population), partly due to upregulation of coagulation factors (VII, VIII, fibrinogen) and impaired fibrinolysis. Severe infections contribute to ~25% of mortality in untreated cases. Metabolic complications encompass nonalcoholic fatty liver disease (NAFLD), dyslipidemia (elevated LDL, triglycerides; low HDL), and metabolic syndrome. Neuro-ophthalmologic sequelae include idiopathic intracranial hypertension (pseudotumor cerebri) and visual field defects in patients with pituitary macroadenomas. Rare but life-threatening complications include adrenal crisis upon abrupt glucocorticoid withdrawal (in exogenous cases) and opportunistic infections such as Pneumocystis jirovecii pneumonia.

Diagnosis relies on a stepwise biochemical approach. First-line screening tests include: (1) late-night salivary cortisol (≥2 measurements; cutoff >0.18 µg/dL or 5 nmol/L); (2) 24-hour urinary free cortisol (UFC; ≥2 collections; cutoff >45–100 µg/24h depending on assay); and (3) low-dose dexamethasone suppression test (1 mg overnight or 0.5 mg q6h for 48 h; failure to suppress serum cortisol to <1.8 µg/dL or 50 nmol/L). Discordant results warrant repeat testing and exclusion of confounders (e.g., depression, alcohol use, medications affecting cortisol metabolism). Once hypercortisolism is confirmed, differential localization follows: plasma ACTH measurement distinguishes ACTH-dependent (ACTH >20 pg/mL) from ACTH-independent (ACTH <5 pg/mL) causes. In ACTH-dependent cases, high-dose dexamethasone suppression test (8 mg over 48 h) and bilateral inferior petrosal sinus sampling (IPSS) with CRH stimulation are gold-standard tools to differentiate Cushing’s disease (pituitary) from ectopic ACTH secretion. Imaging includes pituitary MRI (with contrast, 3T preferred) and chest/abdominal CT or 68Ga-DOTATATE PET/CT for ectopic sources. Adrenal imaging (CT/MRI) is indicated in ACTH-independent cases to identify adenomas, carcinomas, or micronodular hyperplasia.

Differential diagnosis is critical to avoid mismanagement. Pseudo-Cushing states—including major depression, alcoholism, uncontrolled diabetes, and severe obesity—may mimic biochemical features but lack true autonomous cortisol excess; they typically show preserved diurnal rhythm and normal late-night salivary cortisol. Polycystic ovary syndrome (PCOS) shares hirsutism and menstrual disturbances but lacks striae, proximal myopathy, and unequivocal UFC elevation. Anorexia nervosa may cause low cortisol due to hypothalamic suppression but can rarely present with paradoxical hypercortisolemia. Other mimics include familial glucocorticoid resistance (elevated cortisol and ACTH without Cushingoid features), McCune-Albright syndrome (GNAS mutations causing autonomous adrenal nodules), and primary pigmented nodular adrenocortical disease (PPNAD). Exogenous glucocorticoid use must always be rigorously excluded via detailed medication history and serum cortisone/cortisol ratios. Accurate classification dictates therapy: transsphenoidal surgery for Cushing’s disease, adrenalectomy for unilateral adrenal lesions, and multimodal medical management (ketoconazole, osilodrostat, pasireotide, mifepristone) for inoperable or refractory cases.

Cushing’s syndrome is a complex endocrine disorder characterized by chronic exposure to excess glucocorticoids—either endogenous (due to ACTH-dependent or ACTH-independent adrenal overproduction) or exogenous (iatrogenic, from prolonged corticosteroid therapy). Accurate etiological diagnosis is paramount before initiating treatment, as therapeutic strategies differ substantially across subtypes. Management is multidisciplinary, coordinated primarily by endocrinologists, with input from neurosurgeons, interventional radiologists, and oncologists when indicated.

Conservative treatment plays a critical supportive role, particularly in patients awaiting definitive intervention, those deemed medically unfit for surgery, or those with mild or fluctuating hypercortisolism. Lifestyle modification forms the cornerstone: caloric restriction with emphasis on low-glycemic-index carbohydrates, high-quality protein, and calcium/vitamin D supplementation to mitigate osteoporosis risk. Blood pressure control targets <130/80 mmHg using first-line agents such as ACE inhibitors or calcium channel blockers; antihypertensives with mineralocorticoid activity (e.g., spironolactone) are avoided due to potential interference with diagnostic testing. Glycemic management prioritizes insulin sensitizers (e.g., metformin) over sulfonylureas to reduce hypoglycemia risk; insulin may be required in severe cases. Regular weight-bearing exercise—under supervision—is encouraged to preserve muscle mass and bone mineral density, while minimizing fall risk. Psychological support—including cognitive behavioral therapy—is essential given the high prevalence of depression, anxiety, and cognitive impairment. Patients must also undergo rigorous ophthalmologic screening for glaucoma and cataracts, dermatologic evaluation for skin atrophy and striae progression, and baseline dual-energy X-ray absorptiometry (DXA) scanning.

Pharmacologic therapy serves three principal indications: preoperative cortisol reduction (to lower surgical morbidity), bridging therapy for inoperable or recurrent disease, and palliation in malignant ectopic ACTH-secreting tumors. First-line medical options include ketoconazole, a potent inhibitor of adrenal steroidogenesis (CYP11A1, CYP17, CYP21), dosed 200–1200 mg/day with liver enzyme monitoring. Mifepristone—a glucocorticoid receptor antagonist—is uniquely effective for controlling hypertension, hyperglycemia, and psychiatric symptoms in patients with cortisol resistance, though it does not lower serum cortisol levels and thus cannot be used for biochemical monitoring. Pasireotide, a multireceptor somatostatin analog with high affinity for sst5, is FDA-approved for Cushing’s disease refractory to surgery; it reduces ACTH and cortisol in ~25% of patients but carries significant risks of hyperglycemia (requiring concurrent antidiabetic therapy) and QT prolongation. Newer agents under active investigation include osilodrostat (a potent CYP11B1 inhibitor approved in the US/EU) and levoketoconazole (an enantiomer with improved hepatic safety). Medical therapy is rarely curative and requires close biochemical surveillance (late-night salivary cortisol, 24-hour urinary free cortisol) and clinical assessment every 4–6 weeks.

Surgical intervention remains the only potentially curative approach for most forms of endogenous Cushing’s syndrome. Transsphenoidal resection of pituitary corticotroph adenomas (Cushing’s disease) is the gold standard, with remission rates of 70–90% in experienced centers. Preoperative localization via high-resolution 3T MRI and bilateral inferior petrosal sinus sampling (IPSS) is mandatory for lateralization when MRI is inconclusive. For adrenal Cushing’s (adenoma, carcinoma, or primary bilateral macronodular hyperplasia), laparoscopic adrenalectomy is preferred, offering faster recovery and reduced complication rates versus open surgery. In cases of ectopic ACTH syndrome, surgical resection of the source tumor (e.g., bronchial carcinoid, thymic neuroendocrine tumor) is curative if localized and resectable. Bilateral adrenalectomy is reserved for persistent or recurrent Cushing’s disease unresponsive to repeat surgery, radiation, or medical therapy; however, it mandates lifelong glucocorticoid and mineralocorticoid replacement and carries a 10–20% risk of Nelson’s syndrome (progressive corticotroph tumor growth post-adrenalectomy).

Treatment in China offers distinct advantages rooted in infrastructure, expertise, and innovation. Major academic hospitals—including Peking Union Medical College Hospital, Shanghai Ruijin Hospital, and West China Hospital—host nationally accredited Endocrine Centers of Excellence with dedicated Cushing’s multidisciplinary teams. These centers perform over 300 transsphenoidal surgeries annually, achieving remission rates exceeding 85% for microadenomas. China has pioneered advances in intraoperative MRI-guided resection and real-time cortisol monitoring during surgery to optimize adenoma removal. The National Clinical Research Center for Metabolic Diseases supports large-scale prospective registries (e.g., China Cushing Registry), enabling rapid evidence generation. Moreover, domestically developed diagnostics—including highly sensitive LC-MS/MS assays for urinary free cortisol and salivary cortisol—have improved assay precision and accessibility across tier-2 and tier-3 hospitals. Cost-effectiveness is notable: surgical and medical therapies cost approximately 40–60% less than comparable care in Western high-income countries, without compromising quality metrics such as 30-day readmission (<2%) or perioperative mortality (<0.3%).

Post-treatment recovery demands structured, long-term follow-up. After successful surgery, patients require gradual glucocorticoid tapering over 6–18 months, guided by morning cortisol, ACTH, and clinical symptoms of adrenal insufficiency (fatigue, orthostasis, nausea). Lifelong annual screening for recurrence includes late-night salivary cortisol and dexamethasone suppression testing. All patients—regardless of etiology—must receive patient education on sick-day rules: doubling oral hydrocortisone doses during febrile illness or injury, carrying emergency injectable hydrocortisone, and wearing medical alert identification. Bone health maintenance continues indefinitely: bisphosphonates (e.g., zoledronic acid) are initiated if T-score ≤ −2.5 or after fragility fracture. Cardiovascular risk assessment (lipid panel, carotid intima-media thickness) is performed biannually. Psychosocial rehabilitation is integral; many patients experience persistent fatigue and cognitive deficits for 12–24 months post-remission, necessitating neuropsychological evaluation and graded return-to-work programs. Finally, genetic counseling is recommended for patients with bilateral adrenal disease, young-onset Cushing’s, or family history suggestive of MEN1, Carney complex, or PRKAR1A mutations. With comprehensive, individualized care spanning diagnosis through long-term surveillance, sustained remission and restoration of quality of life are achievable goals for the majority of patients with Cushing’s syndrome.